Marked improvement in nail psoriasis during treatment with etanercept.

Psoriasis is a chronic inflammatory skin condition that affects approximately 3% of the population. Up to 50% of patients with psoriasis have concurrent nail psoriasis, up to 30% of patients with skin psoriasis also have psoriatic arthritis and of these, approximately 80% have nail disease. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options. Effective biological agents used in the treatment of moderate to severe chronic plaque psoriasis may represent a new therapeutic modality for this disease. A case of rapid improvement is reported in nail psoriasis under etanercept monotherapy with maintained efficacy following the withdrawal of continued therapy.
AuthorsMercedes Gómez Vázquez, Ramón Navarra Amayuelas
JournalDermatologic therapy (Dermatol Ther) 2011 Sep-Oct Vol. 24 Issue 5 Pg. 498-500 ISSN: 1529-8019 [Electronic] United States
PMID22353156 (Publication Type: Case Reports, Journal Article)
Copyright© 2012 Wiley Periodicals, Inc.
Chemical References
  • Immunoglobulin G
  • Immunologic Factors
  • Receptors, Tumor Necrosis Factor
  • Etanercept
  • Adult
  • Etanercept
  • Humans
  • Immunoglobulin G (therapeutic use)
  • Immunologic Factors (therapeutic use)
  • Male
  • Nail Diseases (drug therapy)
  • Psoriasis (drug therapy)
  • Receptors, Tumor Necrosis Factor (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: